Outcomes of High-Dose Vitamin C Therapy on Patients Diagnosed with COVID-19 Associated ARDS in Intensive Care Units: Multi-Center Retrospective Study
IF 0.3
Q4 CRITICAL CARE MEDICINE
R. Yuksel, F. Yıldırım, C. Kıraklı, S. Temel, Seda Guzeldag, Z. Gullu, Esma Eryilmaz Eren, Meltem Şimşek, H. Sipahioğlu, Kamil İnci, G. Zararsiz, K. Gundogan, M. Sungur
求助PDF
{"title":"Outcomes of High-Dose Vitamin C Therapy on Patients Diagnosed with COVID-19 Associated ARDS in Intensive Care Units: Multi-Center Retrospective Study","authors":"R. Yuksel, F. Yıldırım, C. Kıraklı, S. Temel, Seda Guzeldag, Z. Gullu, Esma Eryilmaz Eren, Meltem Şimşek, H. Sipahioğlu, Kamil İnci, G. Zararsiz, K. Gundogan, M. Sungur","doi":"10.37678/dcybd.2023.3215","DOIUrl":null,"url":null,"abstract":"Background and Aim: The new type of Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus 2019-COVID-19) infection is the largest pandemic in the last decade. Acute respiratory distress syndrome is the complication with the highest mortality rate of this infection and there is no adequate treatment with proven efficacy to reduce mortality. This multi-center, retrospective study aimed to determine the effect of high-dose vitamin C on survival and other endpoints in invasively ventilated ARDS patients. Method(s): This multi-center, observational retrospective cohort study was performed at five ICU centers between March 2020 and July 2020. Patients with ARDS due to COVID-19 who required IMV were included. High-dose vitamin C group was defined as patients who were treated with vitamin C over 200 mg/kg for four days. Patients who were not given vitamin C treatment were defined as the control group by using propensity score match analysis, as well. The groups were compared about the effects of high-dose vitamin C treatment on ICU mortality. Result(s): A total of 86 patients with a mean age of 67.85 +/- 10.38 were included in the study. 72.1% of the patients were male. Forty-two (49%) patients were in the high dose vitamin C group, and 44 (51%) were in the control group. The mean PaO2/FiO2 at the time of admission to the ICU was 128.27+/-58.69 mmHg (133.63+/-56.51 mmHg in the control group, 122.36+/-61.18 mmHg in the study group, p=0.389). The mortality rate of high dose vitamin C group was lower than the control group (73.8% vs. 90.9%, p = 0.037,respectively). Conclusion(s): As an adjunctive therapy in invasively ventilated patients with COVID-19-associated ARDS, high doses of vitamin C may reduce mortality and development of organ damage. Prospective, randomized controlled studies with larger numbers of patients are needed to confirm these findings.Copyright © 2023, Society of Turkish Intensivists. All rights reserved.","PeriodicalId":40137,"journal":{"name":"Journal of Critical & Intensive Care","volume":"45 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Critical & Intensive Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37678/dcybd.2023.3215","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Background and Aim: The new type of Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus 2019-COVID-19) infection is the largest pandemic in the last decade. Acute respiratory distress syndrome is the complication with the highest mortality rate of this infection and there is no adequate treatment with proven efficacy to reduce mortality. This multi-center, retrospective study aimed to determine the effect of high-dose vitamin C on survival and other endpoints in invasively ventilated ARDS patients. Method(s): This multi-center, observational retrospective cohort study was performed at five ICU centers between March 2020 and July 2020. Patients with ARDS due to COVID-19 who required IMV were included. High-dose vitamin C group was defined as patients who were treated with vitamin C over 200 mg/kg for four days. Patients who were not given vitamin C treatment were defined as the control group by using propensity score match analysis, as well. The groups were compared about the effects of high-dose vitamin C treatment on ICU mortality. Result(s): A total of 86 patients with a mean age of 67.85 +/- 10.38 were included in the study. 72.1% of the patients were male. Forty-two (49%) patients were in the high dose vitamin C group, and 44 (51%) were in the control group. The mean PaO2/FiO2 at the time of admission to the ICU was 128.27+/-58.69 mmHg (133.63+/-56.51 mmHg in the control group, 122.36+/-61.18 mmHg in the study group, p=0.389). The mortality rate of high dose vitamin C group was lower than the control group (73.8% vs. 90.9%, p = 0.037,respectively). Conclusion(s): As an adjunctive therapy in invasively ventilated patients with COVID-19-associated ARDS, high doses of vitamin C may reduce mortality and development of organ damage. Prospective, randomized controlled studies with larger numbers of patients are needed to confirm these findings.Copyright © 2023, Society of Turkish Intensivists. All rights reserved.
高剂量维生素C治疗重症监护病房诊断为COVID-19相关ARDS患者的结局:多中心回顾性研究
背景与目的:新型严重急性呼吸综合征冠状病毒2型(冠状病毒2019-COVID-19)感染是近十年来最大规模的大流行。急性呼吸窘迫综合征是这种感染死亡率最高的并发症,目前尚无经证实有效的适当治疗方法来降低死亡率。这项多中心、回顾性研究旨在确定高剂量维生素C对有创通气ARDS患者生存和其他终点的影响。方法:这项多中心、观察性回顾性队列研究于2020年3月至2020年7月在5个ICU中心进行。纳入了需要IMV的COVID-19所致ARDS患者。高剂量维生素C组定义为维生素C≥200mg /kg连续4天治疗的患者。通过倾向评分匹配分析,将未给予维生素C治疗的患者定义为对照组。比较两组大剂量维生素C治疗对ICU病死率的影响。结果:共纳入86例患者,平均年龄67.85±10.38岁。男性占72.1%。高剂量维生素C组42例(49%),对照组44例(51%)。入院时平均PaO2/FiO2为128.27+/-58.69 mmHg(对照组133.63+/-56.51 mmHg,研究组122.36+/-61.18 mmHg, p=0.389)。高剂量维生素C组死亡率低于对照组(73.8% vs. 90.9%, p = 0.037)。结论:高剂量维生素C作为有创通气的covid -19相关ARDS患者的辅助治疗可降低死亡率和器官损害的发生。需要更多患者的前瞻性、随机对照研究来证实这些发现。版权所有©2023,土耳其集约化协会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。